BioDelivery Sciences Announces Agreement with CVS/Caremark for
BELBUCA® and BUNAVAIL®
RALEIGH, NC June 21, 2017 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has signed
an agreement with CVS/Caremark extending access to both BELBUCA® (buprenorphine) buccal film (CIII) and BUNAVAIL® (buprenorphine and
naloxone) buccal film (CIII) through 2020. The agreement is important as CVS/Caremark represents a significant portion of the covered lives in the United States.
BDSI reacquired BELBUCA from Endo Pharmaceuticals in January 2017 and subsequently relaunched the product. Prescription sales for BELBUCA reached their
highest point in May 2017 since the product was launched by Endo in early 2016 and continues to grow in June. Weekly sales for BELBUCA for the week ending June 9, 2017 (1,657 prescriptions) exceeded the previous peak from December 2016 for the
first time according to data from Symphony Health.
We are pleased with the momentum we are beginning to see with BELBUCA as well as the execution
of new managed care contracts, such as the CVS/Caremark agreement which goes through 2020, said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI. We have seen an overall increase in BELBUCA sales since
relaunching the product, and for the first time, we recently exceeded both monthly and weekly sales levels achieved by Endo, suggesting that our current strategy, although early in the process, appears to be working as planned. Furthermore, we
believe the continued focus on responsible use of opioids and actions taken by FDA in this regard bode well for BELBUCAs growth prospects.
About BioDelivery Sciences International
Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing
important unmet medical needs.
BDSIs development strategy focuses on the utilization of the FDAs 505(b)(2) approval process. This regulatory
pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.
BDSIs area of focus
is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs.
BDSIs marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. BDSIs headquarters is in Raleigh, North
For more information, please visit or follow us:
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. ONSOLIS® (fentanyl buccal
soluble film) (CII) is licensed in the U.S. to Collegium Pharmaceutical pursuant to the U.S. licensing and development agreement between BDSI and Collegium. For full prescribing information and important safety information on BDSI products,
including BOXED WARNINGS for ONSOLIS, please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety
information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the Company) related
thereto contain, or may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation, statements with respect to the Companys plans, objectives, projections, expectations and intentions and other statements identified by words such as projects,
may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, potential or
similar expressions. These statements are based upon the current beliefs and expectations of the Companys management and are subject to significant risks and uncertainties, including those detailed in the Companys filings with the
Securities and Exchange Commission. Actual results (including, without limitation, the actual impact on the Companys sales as a result of the managed care contract described herein) may differ significantly from those set forth in the
forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Companys control). The Company undertakes no
obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered trademarks of BioDelivery Sciences
International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.
© 2017 BioDelivery Sciences International, Inc. All rights reserved.
Matthew P. Duffy
LifeSci Advisors, LLC
Senior Vice President, Corporate and Business Development
BioDelivery Sciences International, Inc.
Susan Forman/Laura Radocaj
Dian Griesel Intl.